Stocktoria

PLIANT THERAPEUTICS, INC. PLRX

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-06-03
Chart by TradingView
3/9
Piotroski F — financial health
-7.54
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$0$0$1.6M$9.7M$7.6M
Operating income-$156.4M-$228.4M-$184.1M-$127.2M-$97.5M
Net income-$149.3M-$210.3M-$161.3M-$123.3M-$97.3M
Operating cash flow-$128.3M-$155.5M-$116.4M-$94.6M-$75.4M
Free cash flow-$128.7M-$159.4M-$117.3M-$96.4M-$77.4M
Total assets$225.2M$396.9M$512.2M$350.6M$221.2M
Total liabilities$44.0M$92.9M$38.6M$37.3M$22.2M
Shareholders' equity$181.2M$304.1M$473.6M$313.3M$199.1M
Ratios
Operating margin-11654.7%-1313.4%-1288.1%
Net margin-10211.1%-1273.3%-1284.5%
FCF margin-7422.9%-995.3%-1022.1%
Return on assets-66.3%-53.0%-31.5%-35.2%-44.0%
Return on equity-82.4%-69.2%-34.1%-39.4%-48.9%
Debt / equity0.00×0.10×0.02×0.03×0.00×
Current ratio12.0010.9117.7214.2312.44
Revenue growth-100.0%-83.7%27.9%-81.9%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC1,852,842$2.3M
Point72 Asset Management, L.P.47,054$59,288

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -7.54 (distress)

  • Working capital / assets 0.8
  • Retained earnings / assets -3.816
  • EBIT / assets -0.694
  • Equity / liabilities 4.116

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001746473 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.